Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
about
CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbilsLong-term protective immune response elicited by vaccination with an expression genomic library of Toxoplasma gondii.BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge.Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.Leishmaniasis: current status of vaccine developmentRecombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice.Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c miceThe MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity.Effects of particle size on toll-like receptor 9-mediated cytokine profiles.A review of adjuvants for Leishmania vaccine candidates.Spir2; a novel QTL on chromosome 4 contributes to susceptibility to pneumococcal infection in mice.MyD88 and TLR9 dependent immune responses mediate resistance to Leishmania guyanensis infections, irrespective of Leishmania RNA virus burdenLocal delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice.Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durabilityAdjuvants for Leishmania vaccines: from models to clinical application.Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvantTweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectivesVaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infectionDNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemiaCoencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c miceImmunostimulatory responses to crude extracts of Warburgia ugandensis (Sprague) subsp ugandensis (Canellaceae) by BALB/c mice infected with Leishmania major.Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae.Toll-like receptors in leishmania infections: guardians or promoters?Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral ReseA plasmid containing CpG ODN as vaccine adjuvant against grass carp reovirus in grass carp Ctenopharyngodon idella.Dectin-1 Positive Dendritic Cells Expand after Infection with Leishmania major Parasites and Represent Promising Targets for Vaccine Development.A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice
P2860
Q30446957-E0694CCA-F2E4-4B4C-BBE4-79F9D6B1F480Q30786522-B66A6BA8-6481-40EC-91D9-F17BD6C3E335Q33633286-F3BE05E0-063A-4771-9454-75073C22741CQ33787237-BA8D5832-E36C-4A5B-B5FE-3AA14A28C199Q33941719-1F9CD4E7-3936-470E-AC5A-2E099C208204Q34007162-A3722FDD-07F9-44CD-8035-0E36EEDC4D7CQ34008507-BD908897-02AA-4583-934F-7E53013F2973Q34118325-3CD1AC13-CA3D-4F6F-B06C-41F7892F52DCQ34123352-2CB908DC-F0FF-496C-83DE-840E80BE6B61Q34451057-778A1F6D-8826-4FC1-A39B-07C4B05E79A6Q34540279-CDE6B878-2D57-418C-AAD1-6D0F2290B92AQ34647684-5A639FD6-2ED1-4BFE-B2D3-B977BDA4BEC4Q34664636-F1F6A06C-36EF-427A-9656-7CC217200CAAQ35163825-A1A9E3D2-A0DC-4021-AA92-0707F78C6D38Q35182216-BCF623C6-D040-4DBD-9679-0E7A0BB54EADQ35801755-3462FD61-CCAD-4ADD-BD95-01206D564C98Q35802037-990D306D-5BE0-45A4-96A2-41A5332F1CCBQ36021357-9EB871EE-DAF0-4050-99A8-9F9456B22C21Q36141819-884AB44B-DC90-47EF-9AD8-F5B45EF1E34BQ36171257-07004F09-01F4-4FC8-8119-8B8730D1F22CQ36369774-A794BC67-EDD3-4CA2-965C-ACA1C647AC16Q36445502-AEF76860-3DA8-42B4-9904-DBA4FA12FB10Q36525130-2C05623C-9D01-4CCE-8554-74723CE222FCQ36539044-92A9DF8E-506C-4F98-BFCF-431AB0CF2FD5Q37624078-70D66386-79CE-4470-8C38-619EBD615DDFQ37870760-EE7954DD-5745-4B48-A908-656648294E55Q38004493-79F4761D-0651-446E-BCFF-B2DC9D2A863AQ38947443-ED4218E9-8A6C-480F-B4FC-336040C4EBF1Q45001354-9A185CCA-BB75-4091-B792-16247130D47AQ52726750-CF5E4C8D-BB1C-440D-8FE5-3E183157ACD8Q59127186-95DA21CF-7EFB-4320-AEC8-57BC9C766A9F
P2860
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@ast
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@en
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@nl
type
label
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@ast
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@en
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@nl
prefLabel
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@ast
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@en
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
@nl
P2860
P1476
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
@en
P2093
Blackwell JM
P2860
P304
P407
P577
1999-08-01T00:00:00Z